SEC Form 4 · accession 0001209191-16-090169
aTYR PHARMA INC · LIFE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sanuj K. Ravindran
Officer — Chief Business Officer
Period of report
Jan 4, 2016
Accepted (ET)
Jan 6, 2016 · 8:22 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001339970
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $9.13 | Jan 4, 2016 | A | 153,000 | A | — | Jan 4, 2026 | Common Stock | 153,000 | 153,000 | D |
| Employee Stock Option (right to buy)F2 | $9.13 | Jan 4, 2016 | A | 10,750 | A | — | — | Common Stock | 10,750 | 10,750 | D |
Explanation of responses
- F11/4th of the shares subject to this option shall vest and become exercisable on January 4, 2017 and the remaining shares subject to this option shall vest and become exercisable in 36 equal monthly installments, such that this option is fully exercisable on January 4, 2020. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.
- F2The shares subject to this option shall vest and become exercisable, if at all, in 48 equal monthly installments upon the achievement of certain performance goals, which must be achieved by January 4, 2018, or such option will be subject to immediate forfeiture. This option is subject to accelerated vesting upon termination without cause upon a change of control of the issuer.